Avanti™ DMG-PEG2000

1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 is a lipid excipient designed for the preparation of lipid nanoparticles (LNPs) for RNA delivery. It is derived from dimyristoyl glycerol (DMG) and exhibits similar properties as phospholipids in the way it associates with membranes.

 

DMG-PEG 2000 has been used to create a lipid nanoparticle tailored for microRNA, mRNA, and short interfering RNA (siRNA) delivery. This lipid nanoparticle has been crucial in gene regulation studies and therapeutic interventions.

DMG-PEG 2000 has also found uses in liposome preparation and LNP preparation for siRNA (small interfering RNA) delivery in developing the COVID-19 vaccine. It manufactures lipid nanoparticles used in mRNA vaccines

It's had a significant impact on advanced cancer treatment research. In anticancer drug delivery studies, DMG-PEG 2000 has been used in liposome preparations to facilitate the delivery of anticancer drugs targeting hepatocellular, gastrointestinal, neuroendocrine, and adrenocortical carcinoma.

 

Polyethylene glycol (PEG)-lipids have been the polymer-lipid conjugate of choice for lipid formulations for decades. PEG-lipids are used increase systemic circulation times, mediate indirect targeting capabilities, promote LNP self-assembly, control size and aid in storage stability. Particles containing PEG-lipids are able to bypass the reticulo-endothelial system, giving them their nickname - “stealth agents”.  The DMG lipid anchor has 2 saturated 14-carbon chains and an easily cleaved linker aiding in PEG shedding that will enable higher liver tropism when administered systemically.

Functions include:
- Increased half life when administered systemically
- Aids in storage ability
- Helps obtain small particle sizes
 

Whats next?

Speak with an expert about this exclusive product Explore research grade alternative of this product Add to favourites

View resources